Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States.
Ruxolitinib cream resulted in a 49% reduction in affected body surface area in patients with moderate atopic dermatitis, but results should be interpreted with caution due to the study's observational design.
Where it sits
this study against the rest of the lixisenatide corpusSummary and findings
This study examined real-world outcomes of ruxolitinib cream compared to systemic therapies in patients with moderate atopic dermatitis. The analysis included 619 patients, with a mean age of 39.1 years. The study reported a 49% reduction in affected body surface area with ruxolitinib cream.
Abstract
<h4>Purpose</h4>Ruxolitinib cream (Janus kinase [JAK]1/JAK2 inhibitor) was effective and well tolerated in clinical trials of patients with atopic dermatitis (AD). We examined real-world outcomes among patients with moderate AD treated with ruxolitinib cream or systemic therapies.<h4>Methods</h4>Physician-reported data for adults with moderate AD (physician assessed at current treatment initiation) from the Adelphi AD Disease Specific Programme<sup>™</sup> (August 2022-March 2023) were analyzed descriptively. Patients treated with ruxolitinib cream, traditional systemic immunosuppressants, oral JAK inhibitors, or biologics comprised 4 mutually exclusive cohorts.<h4>Results</h4>Among 619 patients (mean age, 39.1 y; 50% female; 79% White), mean affected body surface area (BSA) was reduced from treatment initiation by 49% with ruxolitinib cream, 35% with systemic immunosuppressants, 61% with oral JAK inhibitors, and 55% with biologics. Nearly half of patients (48.4%) had reduced physician-reported disease severity with ruxolitinib cream versus 6.3%, 51.5%, and 46.4% with systemic immunosuppressants, oral JAK inhibitors, and biologics, respectively. Results were similar among patients with baseline affected BSA ≤20%.<h4>Conclusions</h4>Physician-reported outcomes show that ruxolitinib cream monotherapy substantially reduced the extent and severity of moderate AD, suggesting that it provides an effective topical treatment option in these specific populations.
Background
This paper addresses the effectiveness of ruxolitinib cream in treating moderate atopic dermatitis (AD) in a real-world setting, contrasting it with systemic therapies. Prior clinical trials indicated that ruxolitinib cream was effective and well tolerated, but real-world data is essential to understand its performance outside controlled environments. This study aims to provide insights into how ruxolitinib cream compares to other treatment options in routine clinical practice.
Methods
The study utilized physician-reported data from the Adelphi AD Disease Specific Programme, analyzing outcomes from August 2022 to March 2023. It included adults with moderate AD and categorized them into four cohorts based on treatment: ruxolitinib cream, traditional systemic immunosuppressants, oral JAK inhibitors, and biologics. The primary outcome was the reduction in affected body surface area, while secondary outcomes included physician-reported disease severity.
Results
The primary finding was that the mean affected body surface area (BSA) reduced by 49% with ruxolitinib cream. Comparatively, reductions were reported as 35% with systemic immunosuppressants, 61% with oral JAK inhibitors, and 55% with biologics. Additionally, 48.4% of patients treated with ruxolitinib cream experienced reduced disease severity, which was higher than the 6.3% for systemic immunosuppressants but lower than the 51.5% for oral JAK inhibitors and 46.4% for biologics.
Interpretation
The results suggest that ruxolitinib cream may provide a substantial reduction in the extent and severity of moderate AD, although the effect size compared to systemic therapies varies. While the findings are statistically significant, the clinical relevance may be limited by the lack of a controlled study design and potential biases in physician-reported outcomes. The study's observational nature and reliance on physician assessments may confound the results, indicating a need for cautious interpretation in clinical practice.
Key findings
- Mean affected body surface area (BSA) reduced by 49% with ruxolitinib cream.
- Mean affected BSA reduced by 35% with systemic immunosuppressants.
- Mean affected BSA reduced by 61% with oral JAK inhibitors.
- Mean affected BSA reduced by 55% with biologics.
- 48.4% of patients reported reduced disease severity with ruxolitinib cream.
- 6.3%, 51.5%, and 46.4% reported reduced severity with systemic immunosuppressants, oral JAK inhibitors, and biologics, respectively.
Limitations
- Physician-reported data may introduce bias.
- Lacks randomized controlled trial design.
- Sample may not represent the broader population.
- Short duration of follow-up.
- Not reported in abstract.